Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Jul 30, 2026 | $1.59 | +32.5% | $2.51B | +9.9% | $1.80 |
| Q1 FY26ended Mar 31, 2026 | Apr 30, 2026 | $0.93 | −40.8% | $2.18B | −4.9% | $1.07 |
| Q4 FY25ended Dec 31, 2025 | — | $0.92 | −67.4% | $1.97B | −12.1% | — |
| Q3 FY25ended Sep 30, 2025 | — | $0.40 | −73.9% | $2.20B | −10.6% | — |
| Q2 FY25ended Jun 30, 2025 | — | $1.20 | −38.1% | $2.29B | −3.2% | — |
| Q1 FY25ended Mar 31, 2025 | — | $1.57 | +12.9% | $2.29B | −0.9% | — |
| Q4 FY24ended Dec 31, 2024 | — | $2.82 | +8.5% | $2.25B | +1.7% | — |
| Q3 FY24ended Sep 30, 2024 | — | $1.53 | +2.7% | $2.46B | +8.7% |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Eastman Chemical shares, not any token. As of Jul 30, 2026, from Massive's standardised financials and the earnings calendar.
| — |
| Q2 FY24ended Jun 30, 2024 | — | $1.94 | — | $2.36B | — | — |
| Q1 FY24ended Mar 31, 2024 | — | $1.39 | — | $2.31B | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $2.60 | — | $2.21B | — | — |
| Q3 FY23ended Sep 30, 2023 | — | $1.49 | — | $2.27B | — | — |